Clinical and pathological correlations of marrow PUMA and P53 expressions in myelodysplastic syndromes

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0463|123|5|445-451

ISSN： 0903-4641

Source： APMIS (ELECTRONIC), Vol.123, Iss.5, 2015-05, pp. : 445-451

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes: Cytogenetic Characterization

By  

Acta Haematologica, Vol. 128, Iss. 3, 2012-08 ,pp. : 170-177

Karger

Access to resources Recommend Favorite

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 6, 2015-06 ,pp. : 463-463

John Wiley & Sons Inc

Access to resources Recommend Favorite

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 91-99

John Wiley & Sons Inc

Access to resources Recommend Favorite

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 91-99

John Wiley & Sons Inc

Access to resources Recommend Favorite

Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 137-141

John Wiley & Sons Inc

Access to resources Recommend Favorite